Literature DB >> 16714233

Evaluation of an ex vivo model implication for carrier-mediated retinal drug delivery.

Viral Kansara1, Ashim K Mitra.   

Abstract

PURPOSE: The purpose of this study was to evaluate the implication of an ex vivo model for carrier-mediated retinal drug delivery using an Ussing chamber system.
METHODS: Dutch Belted Pigmented rabbits weighing 2-2.5 kg were used in these studies. Excised posterior segment tissues (RPE-choroid-sclera and sclera), mounted on the Ussing chamber, were used as an ex vivo model. Transport studies were carried out across sclera and RPE-choroid-sclera (RCS) tissue preparations in the sclera to retina (S --> R) and retina to sclera (R --> S) directions for 3 hr at 37 degrees C. The model was validated by permeability studies with paracellular and transcellular markers ([(3)H]mannitol and [(14)C]diazepam, respectively), tissue viability studies (bioelectrical and biochemical assays), and tissue histology and electron microscopy studies. Functional presence of a carrier-mediated transport system for folic acid (folate receptor alpha) was investigated on the basolateral side of the rabbit retina.
RESULTS: Results from bioelectrical, biochemical, and histological evaluation of tissue provide evidence that the RCS tissue preparation remains viable during the period of transport study. Permeability values of [(3)H]mannitol across sclera were 4.18 +/- 1.09 x 10(- 5) cm/s (R --> S) and 4.11 +/- 1.09 x 10(- 5) cm/s (S --> R) and across RCS were 1.77 +/- 0.31 x 10(- 5) cm/s (S --> R) and 1.60 +/- 0.19 x 10(- 5) cm/s (R --> S). Permeability values of [(14)C]diazepam across sclera were 2.37 +/- 0.38 x 10(- 5) cm/s (R --> S) and 2.70 +/- 0.70 x 10(- 5) cm/s (S --> R) and across RCS were 3.12 +/- 0.12 x 10(- 5) cm/s (R --> S) and 2.77 +/- 0.25 x 10(- 5)cm/s (S --> R). The rate of [(3)H]folic acid transport across RCS was found to be significantly higher in the S -->R direction (16.34 +/- 0.94 fmoles min(-1) cm(-2)) as compared with R --> S direction (9.38 +/- 1.44 fmoles min(-1) cm(-2)) and nearly 10-fold higher across sclera as compared with RCS in both directions. Transport of [(3)H]folic acid was found to be pH and temperature dependent and was inhibited by 44.5%, 35.1%, and 50.3% in the presence of unlabeled folic acid, 5-methyltetrahydrofolate (MTF), and Methotrexate (MTX).
CONCLUSIONS: The RCS tissue preparation mounted on the Ussing chamber system, an ex vivo model, can be a useful tool for identification and characterization of carrier-mediated systems present on RPE (a major barrier for retinal drug delivery) and to study carrier-mediated retinal drug delivery via prodrug derivatization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714233     DOI: 10.1080/02713680600646890

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  5 in total

1.  In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.

Authors:  Paul Missel; James Chastain; Ashim Mitra; Uday Kompella; Viral Kansara; Sridhar Duvvuri; Aniruddha Amrite; Narayan Cheruvu
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

2.  Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Authors:  Rajendra S Kadam; Narayan P S Cheruvu; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

Review 3.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

4.  Light-responsive biomaterials for ocular drug delivery.

Authors:  Hend A M Abdelmohsen; Nikki A Copeland; John G Hardy
Journal:  Drug Deliv Transl Res       Date:  2022-06-24       Impact factor: 4.617

5.  Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Liang Jin; Yijun Pan; Natalie Lan Linh Tran; Leon N Polychronopoulos; Aparna Warrier; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2020-04-08       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.